This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Plato BioPharma Presenting Preclinical Capabilities At PKPD Summit Boston

WESTMINSTER, Colo., March 19, 2013 /PRNewswire/ -- Plato BioPharma, Inc. (PBI) will be presenting their integrated pharmacology capabilities at the "PKPD Summit Boston" in Boston, Massachusetts on March 20, 2013.  The presentation will overview PBI's integrated pharmacology approach.  The presentation will be delivered by Drs. Glenn J. Smits, PhD and Craig F. Plato, PhD, President of Plato BioPharma, Inc.

"Clients trust PBI to deliver complex preclinical proof of concept studies due to our extensive industry experience in disease modeling and discovery pharmacology.  We're participating in the PKPD Summit to detail our broader capabilities and expertise in drug discovery.  We appreciate the challenges of translating preclinical work, and believe PBI is well-positioned to address these challenges and provide disease-relevant PK and PD approaches.  We strive to bring a more creative and partnering approach to the preclinical paradigm to deliver the highest quality science while decreasing the time for enabling decisions thus minimizing cost," said Dr. Plato.

Founded in 2009, Plato BioPharma, Inc. is a leading preclinical contract research organization (CRO).  The company offers expert drug discovery and development capabilities in cardiovascular, renal, pulmonary, and hepatic disease therapeutic areas.  PBI provides an integrated research platform from the in-life phase through clinical chemistry, biomarker and histological analyses.  The company specializes in custom study design and execution of engagements ranging from pharmacokinetics through disease model development and proof-of-concept evaluation.  PBI is headquartered in Westminster, Colorado.

Contact: Bob LeahyPhone: 303-506-6960Email: bleahy@platobiopharma.comWebsite:

SOURCE Plato BioPharma, Inc.
Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,084.49 +33.74 0.20%
S&P 500 2,013.43 +15.91 0.80%
NASDAQ 4,830.47 +19.6820 0.41%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs